News

Quintiles taps OmniComm for early-stage data management

Global CRO Quintiles is reaching out to software provider OmniComm to replace its Phase I eClinical technology, signing a 5-year deal with the Florida company.

AMRI plans to shutter an R&D shop to save cash

Contract drug developer AMRI will close down its Syracuse, NY, facility by midyear, part of an effort to cut costs and realign its business.

InVentiv signs up to get IntelliCell's regenerative drug into the clinic

CRO inVentiv Health is teaming up with IntelliCell BioSciences to get the biotech's regenerative medicine candidate through the IND stage, pitching in to develop a novel treatment for osteoarthritis of the knee.

Certara buys Synchrogenix with its eye on regulatory writing

Certara, an informatics-focused pharma contractor, has bought up specialty CRO Synchrogenix, absorbing a company devoted to regulatory writing with hopes of expanding its market share.

CROs are spending more on merit raises, survey says

On the whole, the CRO industry is increasing its budgets for merit-based pay increases, according to a survey.

Catalent inks a biosimilar alliance with a Chinese drugmaker

Catalent has signed a deal to lend its biologics development technology to China's Zhejiang Hisun Pharmaceuticals and help the drugmaker get working on copies of some top-selling drugs.

Pacira picks Patheon to hit the gas on pain drug production

Pacira Pharmaceuticals is counting on an expanded indication and swell in demand for its surgical pain treatment, and the biotech has inked a deal with contract manufacturer Patheon to collaborate on production in a multiyear agreement.

Bristol-Myers enlists DKSH to push its drugs in Asia

Bristol-Myers Squibb is re-upping with market-access outfit DKSH to dial up its commercialization efforts in Asia, extending a deal signed in 2010.

Parexel amps up its imaging focus in rebranded informatics biz

Parexel International is looking to scale up its capabilities in medical imaging for clinical trials, expanding its eClinical outfit and appointing an industry veteran to steer the way.

Clinipace cozies up to Karyopharm to get its pipeline moving

Clinipace has signed a far-reaching deal with biotech Karyopharm, agreeing to handle a host of studies under a preferred provider arrangement.

Charles River wraps up $179M deal for Galapagos' CRO biz

Charles River Laboratories has closed its bid for two CROs formerly owned by drug developer Galapagos, trading $179 million up front and up to $7 million down the line for Argenta and BioFocus.

Evotec lands two more deals to share risks and rewards of R&D

Germany's Evotec subverts the traditional CRO model by cozying up to its development partners with risk-splitting deals, and the company's approach to R&D has attracted Debiopharm and Convergence Pharmaceuticals with programs in cancer and chronic pain.

AMRI expects its $41M Cedarburg deal to pay off right away

AMRI has wrapped up its $41 million effort to acquire contract manufacturer Cedarburg Pharmaceuticals, and the company says it's in line for an immediate windfall.

Actavis picks Particle Sciences for generics development

Contract developer Particle Sciences has nailed down a deal with Actavis, lending its drug delivery expertise to the generics giant. 

WuXi bets on anti-counterfeiting tech with an eye on drug safety

WuXi PharmaTech, China's largest pharma outsourcing outfit, is investing in a startup that makes tiny, edible bar codes designed to prevent drug counterfeiting, planning to offer the same technology to its manufacturing customers.

Clinipace signs up to get a brain-stimulating device on the U.S. market

Global CRO Clinipace has agreed to manage clinical trials for Nexstim as the Finnish devicemaker works toward FDA approval for its neurostimulation therapy.

BioClinica bags $30M in Big Pharma deals

CRO BioClinica said it inked two long-term deals with major drugmakers totaling $30 million, touting its eClinical technology as driving sponsor interest.

Rho inks a federal bioterror pact with $100M on the line

North Carolina CRO Rho has signed up to help the U.S. government's Biomedical Advanced Research and Development Authority design and conduct clinical trials for treatments that protect against bioterrorism and other public health emergencies, getting in line for as much as $100 million over 5 years.

NephroGenex picks Medpace for kidney disease Phase III

A month removed from a $915 million buyout deal, CRO Medpace has signed on to help biotech NephroGenex get through Phase III with its promising kidney disease candidate.

Quintiles signs on to help BioDelivery get its anti-addiction drug out the door

Raleigh, NC's BioDelivery Sciences is expecting to win FDA approval for its opioid-dependence patch this summer, and the biotech has enlisted global contractor Quintiles to handle the launch.